Agrow is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. Please do not redistribute without permission.

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Evogene completes $4.5 m research expansion

Israeli genomics company Evogene (Rehovot) has completed a $4.5 million, two-stage expansion programme of its R&D facilities that sees a 50% increase in its gene validation and plant growth capacity. Stage one included reconstruction of existing facilities and the addition of a new 1,100 m 2 molecular and tissue culture laboratory, with the second stage focusing on a doubling in area of Evogene's greenhouse site at Gezer. The new laboratories are equipped with custom tailored automated instruments for lab processes, with emphasis on cost optimisation, international environmental safety standards and energy savings. The new facilities will substantially increase the amount and type of research activities that the company can undertake with its proprietary Athlete, EvoBreed and Gene2product computational genomic platforms, the company notes. It is able to clone, transform to model plants and validate over 1,000 genes per year, thus providing the capacity for continuing rapid growth and expansion, it adds.

Advertisement

Topics

What to read next

Advertisement
UsernamePublicRestriction

Register

AG006025

Ask The Analyst

Please fill in the form below to send over your enquiry or check the Ask The Analyst Page to find out more about the service

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel